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for clinicians. Drug-induced effects should be always
considered in differential etiologic diagnosis of vas-
culitis.
We present the case of a patient who developed alve-
olar haemorrhage and rapidly progressive glomeru-
lonephritis due to PTU treatment.
cAse report 
An 81-year-old non-smoker woman was admitted to
our hospital because of cough and haemoptysis. These
symptoms had started one week before the admission
and had gradually become more severe. A toxic nodu-
lar goitre had been diagnosed 10 years before and she
was on PTU 200 mg daily, since then. She had previ-
ously refused radioactive iodine treatment.
No medical history of fever, constitutional symp-
toms, and signs of joint, ocular, skin involvement or
chronic organ failure was reported.
Routine laboratory tests performed one year before
the admission were normal.
On admission, blood pressure was 110/75 mmHg,
heart rate 103 bpm and body temperature 36°C. Res-
piration rate was 20 breaths for minute and oxygen
satu ration was 98% in room air.
Auscultation of the lungs revealed bibasilar crackles
while the remaining physical examination was unre-
markable.
Laboratory tests showed normocytic normochromic
anaemia haemoglobin 8.1 g/dL, reference range 11.5-
-15.5 g/dl, normal white blood cell and platelet counts,
increased C-reactive protein 1.6 mg/dL (< 0.5 mg/dL)
and erythrocyte sedimentation rate 30 mm/h 
(< 20 mm/h). Protein electrophoresis was unremarka -
ble. Thyroid function, liver function and coagulation
tests were normal. Viral hepatitis and HIV serology were
negative as well. Renal function tests showed increased
blood urea nitrogen (120 mg/dL, reference range 17-
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AbstrAct 
Propylthiouracil (PTU) is known to induce antineu-
trophil cytoplasmatic antibody (ANCA) seropositivity;
however, small vessel vasculitis (SVV) with pulmonary
and renal involvement is rare.
We present the case of an 81-year-old woman on
PTU treatment due to toxic nodular goitre who deve -
loped alveolar hemorrhage and rapidly progressive
glomerulonephritis.
The authors highlight the importance of early reco -
gnising drug-induced pulmonary-renal syndrome
(PRS) in order to avoid unnecessary tests, a delay in the
diagnosis and evolution to end-stage kidney disease or
life-threatening conditions.
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IntroductIon
Propylthiouracil (PTU) is commonly used to treat hy-
perthyroidism. Adverse reactions such as fever, rash,
leucopenia, pneumonitis, vasculitis, and lupus-like
syndrome have been largely reported1,2. PTU can in-
duce antineutrophil cytoplasmatic antibody (ANCA)
seropositivity (estimated from 20-64% in reported
studies3,4) but only few patients develop a small vessel
vasculitis (SVV) associated with pulmonary-renal syn-
drome (PRS).
Clinical and laboratory presentation of PRS can be
polymorphic, nonspecific and represents a challenge
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FIGure 1. Chest x-ray showed bilateral heterogeneous 
pulmonary opacities (A) and chest CT scan revealed multifocal
areas of ground-glass opacities and bibasilar honeycomb lung
(B-C)
FIGure 2. A) Masson’s trichrome (MT) 100X: Interstitial 
fibrosis areas (black star) and tubular atrophy (black arrow). 
B) Periodic acid-Schiff (PAS) 400x: Glomerulus with fibrinoid
necrosis (blue arrow) and celular crescent (black arrow). 
C) MT 400x: glomerulus with fibrinoid necrosis (green oval)
and celular crescent (blue oval). D) PAS (200x): glomerulus
with fibrin crescent formation and partial sclerosis of the new
capillary (yellow star); glomerulus with fibrocelular crescent
(black arrow) and Bowman’s capsule rupture (red arrow); 
tubular atrophy and interstitial fibrosis (blue oval); 
mononuclear inflammatory cell infiltrate surrounding 
glomeruli (yellow oval)
-43 mg/dL) and creatinine (2.57 mg/dL, reference
range 0.51-0.95 mg/dL). Urinalysis revealed haema-
turia (erythrocytes 401/L, (< 22/ L) and proteinuria
(100 mg/dL) quantified in the urinalysis as 2,7g/day.
Chest x-ray showed bilateral heterogeneous pul-
monary opacities (Figure 1. A) and chest computo -
rized tomography (CT) scan revealed multifocal areas
of ground-glass opacities and bibasilar honeycomb
lung (Figure 1. B-C).
Flexible bronchoscopy (FB) revealed hyperaemic
bronchial mucosa and haemosiderin-laden macropha -
ges were isolated in bronchoalveolar lavage fluid.
Ultrasound examination of the kidneys was normal.
PRS was suspected and perinuclear ANCA 
(p-ANCA) with antimyeloperoxidase antibody (MPO
126.4 U/ml;  < 20 U/ml) were found to be positive; cy-
toplasmatic ANCA (c-ANCA), anti-nuclear antibody,
antiglomerular basement membrane antibody and re-
maining immunological tests were ne gative.
Renal biopsy revealed SVV with fibrinoid necrosis
with inflamatory mononuclear-cell infiltration, cellu-
lar crescents, rupture of Bowmans capsule, focal seg-
mental glomerulosclerosis, cortical interstitial fibrosis
and tubular atrophy (Figure 2. A-B-C-D).
PTU-induced p-ANCA-positive SVV with pul-
monary and renal involvement was diagnosed.
PTU treatment was stopped; methimazole (5 mg
daily), pulse methylprednisolone (500 mg daily du -
ring 3 days) followed by corticotherapy (1 mg/kg/dai-
ly) and intravenous pulses cyclophosphamide (0.5 g/
m2 biweekly) were started. Due to its immunomodu-
latory properties and in order to prevent Pneumocystis
jirovecii infection, cotrimoxazole was started too.
Symptoms, clinical and laboratory findings improved
(Hemoglobin 10.5 g/dL; Urea 89 mg/dL; Creatinine
1.6 mg/dL; 24 hour-proteinuria 0.95 g/day) within two
months of PTU withdrawal. No leukopenia occurred
and ANCA titre decreased (36.23 U/ml) after six
months of immunosuppressive therapy induction.
Azathioprine (2 mg/kg/day) was used as maintenance
therapy.
dIscussIon
PRS is most commonly due to SVVs, such as ANCA-
related vasculitis (ARV), Goodpastures disease, IgA
nephropathy/Henoch-Schönlein purpura and systemic
lupus erythematosus and there is certainly an overlap
in clinical and laboratory phenotypes among these
SVVs.
ARV includes granulomatosis with polyangiitis, mi-
croscopic polyangiitis, eosinophilic granulomatosis
with polyangitiis, renal-limited vasculitis and drug-in-
duced vasculitis. ARV may present with severe organ
involvement; this is why identification of potentially
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eventually indicated10.
Fatalities are rare11 and PTU-induced ANCA SVV has
a better prognosis than primary ANCA-associated
SVV12.
We report this case of PTU-induced PRS to increase
physicians awareness of the potential risk for the de-
velopment of drug-associated ANCA vasculitis.
correspondence to
Matteo Boattini





1. Vasily DB, Tyler WB. Propylthiouracil-induced cutaneous vas-
culitis. Case presentation and review of the literature. JAMA
1980; 243:458-461.
2. Miyazono K, Okazaki T, Uchida S, et al. Propylthiouracil-indu-
ced diffuse interstitial pneumonitis. Arch Intern Med 1984;
144:1764-1765.
3. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A.
Prevalence of positive anti-neutrophil cytoplasmatic antibody
(ANCA) in patients receiving anti-thyroid medication. Eur J En-
docr 2000; 142:587.
4. Gao Y, Zhao MH. Review article: drug-induced antineutrophil
cytoplasmatic antibodyassociated vasculitis. Nephrology
2009;14:33-41.
5. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term out-
comes of patients with propylthiouracil-induced anti-neutro -
phil cytoplasmatic auto-antibody-associated vasculitis. Rheu-
matology 2008; 47:1515-1520.
6. Luqmani RA, Pathare S, Kwok-Fai TL. How to diagnose and
treat secondary forms of vasculitis. Best Pract Res Clin Rheu-
matol 2005; 19(2):321-336.
7. Dolman KM, Gans ROB, Vervaat TJ, et al. Vasculitis and anti-
neutrophil cytoplasmatic autoantibodies associated with pro-
pylthouracil therapy. Lancet 1993; 342(8872):651-652.
8. Pillinger M, Staud R. Wegener’s granulomatosis in a patient re-
ceiving propylthiouracil for Graves disease. Semin Arthritis
Rheum 1998; 28:124-129.
9. Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-thyroid drugs
and antineutrophil cytoplasmatic antibody positive vasculitis.
A case report and review of the literature. J Clin Endocrinol Me-
tab 1999; 84:13-16.
10. KDIGO Glomerulonephritis Work Group. KDIGO clinical prac-
tice guideline for glomerulonephritis. Kidney Int Suppl 2012;
2:139-274.
11. Batchler N, Holley A. A fatal case of propylthiouracil-induced
ANCA-positive vasculitis. Med Gen Med 2006; 8(4):10.
12. Cao X, Lin W. Clinical study of renal impairment in patients
with propylthiouracil-induced small-vessel vasculitis and pa-
tients with primary ANCA-associated small vessel vasculitis.
Experimental and therapeutic medicine 2013; 5:1619-1622.
reversible causes, such as drugs, is very important.
The drugs most frequently associated with ANCA
seroposivity are antithyroid agents such as PTU and,
less frequently, methimazole and carbimazole. It has
been reported that patients receiving long-term PTU
treatment may develop antibodies directed against neu-
trophil perinuclear antigen (Myeloperoxidase; 
p-ANCA), neutrophil cytoplasmatic antigen (Pro-
teinase 3; c-ANCA) or against other neutrophil anti-
gens such as human leucocyte elastase, lactoferrin,
cathepsin G, azurocidin and bactericidal/permeabili-
ty-increasing protein3,5.
Other drugs implicated in ANCA seropositivity are
penicillamine, hydralazine, minocycline, allopurinol,
procainamide, thiamazole, clozapina, phenitoyn, ri-
fampicin, cefotaxime, sulfasalazine, ciprofloxacin, iso-
niazid and indomethacin6.
PTU induced p-ANCA vasculitis was first reported
in 19937 and the physiopathological mechanism still
remains uncertain. It seems that PTU accumulates in
neutrophils, binding and potencially modifying MPO
antigens, and leading to the formation of autoantibo -
dies in susceptible patients.
ANCA titre usually decreases after PTU withdrawal
but in some cases can remain elevated without evidence
of SVV.
The duration of PTU-treatment prior to clinical pre-
sentation ranged from 1 week to 7 years8.
Drug induced ANCA-associated vasculitis can be as-
sociated with constitutional symptoms, fever, arthral-
gias, arthiritis, cutaneous vasculitis and, less frequent-
ly, with rapidly progressive glomerulonephritis and
alveolar hemorrhage.
Renal involvement is the most common manifesta-
tion9 and can occur with nephritis and acute failure.
Alveolar hemorrhage is a potentially life-threaten-
ing condition: our patient had haemoptysis and anemia
but FB showed no active hemorrhage.
The diagnosis of PTU-induced vasculitis in our pa-
tient was made by observation of clinical findings, high
index of suspicion of PRS, the presence of p-ANCA
seropositivity, renal histology and clinical and labora-
tory improvement documented after PTU discontinu-
ation and immunosuppressive therapy.
The optimal management of drug-associated ANCA
vasculitis consists in discontinuation of the triggering
agent and, in case of lung and kidney involvement, ini-
tiation of corticosteroids and cyclophosphamide. In
case of advanced kidney failure, dialysis-dependency or
difuse alveolar hemorrhage, plasmapheresis can be
